Leukemia, Myelodysplastic Syndromes
Conditions
Keywords
recurrent childhood acute lymphoblastic leukemia, childhood myelodysplastic syndromes, childhood acute lymphoblastic leukemia in remission, recurrent childhood acute myeloid leukemia, childhood acute myeloid leukemia in remission, secondary acute myeloid leukemia, accelerated phase chronic myelogenous leukemia, blastic phase chronic myelogenous leukemia, childhood chronic myelogenous leukemia, relapsing chronic myelogenous leukemia, de novo myelodysplastic syndromes, secondary myelodysplastic syndromes, previously treated myelodysplastic syndromes
Brief summary
RATIONALE: Chemotherapy, such as fludarabine and thiotepa, and radiation therapy may destroy cancerous blood-forming cells (stem cells) in the blood and bone marrow. Giving healthy stem cells from a donor whose blood closely resembles the patient's blood will help the patient's bone marrow make new stem cells that become red blood cells, white blood cells, and platelets. PURPOSE: This phase I/II trial is studying the side effects of total-body irradiation, fludarabine, and thiotepa and to see how well they work in treating young patients who are undergoing a donor stem cell transplant for hematologic cancer.
Detailed description
OBJECTIVES: Primary * Determine the safety of a conditioning regimen without anti-thymocyte globulin comprising total body irradiation, thiotepa, and fludarabine followed by CD34-positive-selected haploidentical allogeneic peripheral blood stem cell transplantation in young patients with life-threatening hematologic malignancies. Secondary * Determine the risk for severe graft-vs-host disease in patients treated with this regimen. * Determine the kinetics of immune reconstitution in patients treated with this regimen. * Determine the risk for life-threatening infections in patients treated with this regimen. OUTLINE: * Conditioning regimen: Patients 7 years of age and under undergo total body irradiation twice daily on days -9 to -7. Patients over 7 years of age undergo total body irradiation once on day -7. All patients receive fludarabine IV once daily on days -6 to -2 and thiotepa IV over 2 hours twice on day -5. * CD34-positive (CD34+)-selected haploidentical allogeneic peripheral blood stem cell transplantation (PBSCT): Patients undergo CD34+-selected allogeneic PBSCT on days 0 and 2. Patients with acute lymphoblastic leukemia or CNS disease also receive methotrexate intrathecally twice before transplantation and 4 times after day 35 post-transplantation. Male patients with lymphoid malignancies undergo additional radiotherapy to the testes. After completion of study treatment, patients are followed for at least 100 days, at 1 year, and then periodically thereafter. PROJECTED ACCRUAL: A total of 20 patients (10 patients ≤ 7 years of age and 10 patients \> 7 years of age) will be accrued for this study within 3 years.
Interventions
DRUGfludarabine phosphate
DRUGthiotepa
PROCEDUREperipheral blood stem cell transplantation
RADIATIONradiation therapy
Sponsors
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Study design
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 20 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Diagnosis of a life-threatening hematologic malignancy, including any of the following: * Acute leukemia advanced beyond first remission * Acute leukemia in first remission\* with very high-risk prognostic features, including any of the following: * Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) * ALL or acute myeloid leukemia (AML) with 11q23 chromosomal abnormality * Hypodiploid ALL * Failed to achieve first remission within 1 month after induction therapy * Secondary AML * Myelodysplastic syndromes with International Prognostic Index score \> 1 * Chronic myelogenous leukemia in accelerated or blast phase NOTE: \*Must be approved by PCC * Haploidentical family donor available * No suitable HLA-matched related or unrelated donor available * No related donor mismatched for a single HLA-A, -B, -C, -DRB1, or -DQB1 antigen available PATIENT CHARACTERISTICS: Age * Under 21 Performance status * Not specified Life expectancy * At least 6 months Hematopoietic * Not specified Hepatic * SGPT and SGOT \< 2 times upper limit of normal (ULN)\* * Bilirubin \< 2 times ULN\* NOTE: \*Unless due to malignancy Renal * Not specified Cardiovascular * Ejection fraction ≥ 45% Pulmonary * DLCO ≥ 60% of predicted Other * Not pregnant or nursing * Fertile patients must use effective contraception * HIV negative PRIOR CONCURRENT THERAPY: Biologic therapy * No second bone marrow transplantation, after a first regimen containing total body irradiation * No concurrent growth factors until day 21 post-transplantation Chemotherapy * Not specified Endocrine therapy * Not specified Radiotherapy * See Biologic therapy Surgery * Not specified
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | — |
Secondary
| Measure | Time frame |
|---|---|
| Risk of severe graft-versus-host disease | — |
| Kinetics of immune reconstitution | — |
| Risk of life-threatening infections | — |
Countries
United States
Outcome results
None listed